Description
PT-141 10mg – Research-Grade Peptide for CNS and Peptide Signaling Studies
Delivery: Laboratory Research-Grade, 10mg Vial
PT-141 10mg is a synthetic, research-grade peptide developed for laboratory investigations involving central nervous system (CNS) receptor signaling, peptide–receptor interactions, and molecular pathway research. It is commonly used in in vitro and ex vivo studies of peptide pharmacology, receptor activation, and cellular signaling mechanisms.
This product is strictly intended for research purposes only and is not approved for human consumption, clinical, or veterinary use.
What Is PT-141?
PT-141 is a synthetic peptide that interacts with specific receptors in CNS models and laboratory systems. In research settings, PT-141 is used to investigate:
• Peptide–receptor binding and signal transduction mechanisms
• CNS receptor pharmacology and peptide-mediated signaling
• Molecular pathways associated with receptor activation
• Experimental peptide biology and mechanistic studies
• Dose-response and stability studies under controlled laboratory conditions
All applications are strictly non-clinical and limited to scientific laboratory research.
Research Applications of PT-141 10mg
PT-141 10mg is suitable for laboratory research including:
• CNS Receptor Signaling Studies – Analysis of receptor–peptide interactions in controlled models
• Peptide Pharmacology Research – Exploration of synthetic peptide activity and receptor modulation
• Molecular Mechanism Studies – Investigation of peptide-mediated signaling pathways in vitro or ex vivo
• Dose-Response and Stability Investigations – Laboratory evaluation of peptide kinetics and binding profiles
• Experimental Peptide Biology – Mechanistic research into synthetic peptide compounds
All uses are limited to scientific research purposes only.
Product Specifications
• Peptide: PT-141
• Concentration: 10mg per vial
• Grade: Research-Grade
• Storage: Store according to standard peptide laboratory protocols
The 10mg format provides flexibility for dose-response studies, pilot experiments, and multi-phase laboratory research.
Purity & Quality Assurance
ExoLabz peptides are manufactured under strict quality control standards. ExoLabz products undergo independent third-party testing to verify identity, purity, and content. Results are published on this site.
Researchers may independently submit the product for verification. If specifications are not met, ExoLabz provides a refund and testing reimbursement, ensuring full transparency and research integrity.
Important Legal Disclaimer
For Research Purposes Only
PT-141 10mg is intended strictly for scientific research and laboratory investigation. It is not approved by the FDA, Health Canada, or any other regulatory authority. This product is not for human consumption, clinical, therapeutic, or veterinary use.
By purchasing this product, the buyer acknowledges and agrees that it will be used exclusively for lawful laboratory research purposes.
Compound identity and specification
Identity data for PT-141 (bremelanotide), published so the material can be checked against an independent record rather than taken on trust. The formula, mass and registry number below are verified against PubChem and can be looked up directly.
| Compound | PT-141 (bremelanotide) |
|---|---|
| Sequence | Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH |
| Molecular formula | C50H68N14O10 |
| Molecular mass | 1025.2 g/mol |
| CAS registry number | 189691-06-3 |
| PubChem | CID 9941379 |
| Vial content | 10 mg |
| Physical form | Lyophilised powder in a sealed vial |
| Analysis | Third-party HPLC; the result for this product is published on this page |
| Supplied for | Laboratory research use only |
Analytical note — PT-141 (bremelanotide). A cyclic lactam peptide, and its ring is what distinguishes it analytically from the linear alternatives. It differs from Melanotan II by one atom of the C-terminus: a free acid here against an amide there, about 1 Da apart, which is why a rounded mass on a certificate cannot tell them apart.
How the compound is written
The same material appears under several written forms. PT-141 and PT 141 are the same development code with and without the hyphen, PT141 is the closed form, and bremelanotide is the international non-proprietary name for the molecule. All of them refer to the cyclic heptapeptide described in the identity table above, and the CAS registry number is the value to match when comparing one listing against another.
Checking this material against its certificate
A cyclic peptide gives an analyst one check that a linear peptide does not. Closing the ring removes a molecule of water, so the uncyclised precursor is 18 Da heavier than the finished compound. On a mass spectrum, a peak 18 Da above the expected mass is the signature of incomplete cyclisation, and it is the first thing worth looking for on a certificate for this compound.
Two further figures decide what a purity number means. The counter-ion is usually trifluoroacetate carried over from purification, and it contributes mass that is not peptide; net peptide content is the figure that accounts for it. A certificate reporting HPLC purity without stating net peptide content describes how clean the peptide is, not how much of it is in the vial. Both are set out in net peptide content and TFA and acetate counter-ions.
Certificates are published on this site rather than shipped with orders. A vial is matched to its certificate by cap and crimp colour against the photographs on the report itself, and the full set is on the certificates of analysis page.
Handling the vial on arrival
The compound is supplied lyophilised, which is the form that tolerates a domestic transit window at ambient temperature. What matters is what happens after delivery, and it is the same for every peptide in this catalogue: bring the vial to room temperature before opening it, keep repeat entries to a minimum, and record the reconstitution date against the certificate for the material. Receiving a research peptide shipment and aliquoting reconstituted peptides set out the routine.
Identity references The molecular formula, molecular mass and CAS registry number above are taken from the PubChem record linked in the table, not from a supplier datasheet, so every figure can be checked against an independent source in one click. Sequences are given as reported in the peptide literature, in the one-letter or three-letter convention as appropriate, with any non-standard residue named in full. Where a compound exists in more than one form — a free peptide and a metal complex, a fragment and its parent protein, a modified and an unmodified analog — the form supplied is the one identified here, and the mass on the certificate of analysis is what distinguishes it.
Research Literature
Peer-reviewed studies involving this compound and its class. All findings listed are from in vitro, cell culture or animal models and are provided for scientific reference only. This product is supplied for laboratory research and is not approved for human consumption, clinical, or veterinary use.
- Suzuki S, et al. Anticancer Res. 2024;44(9):3875-3883. In human glioblastoma cell lines, measured survivin protein expression and cell death, blocked by melanocortin receptor antagonists and by survivin overexpression. Source · PMID 39197897
- Yuan XC, Tao YX Biomolecules. 2022;12(10):1407. Review cataloguing ligand pharmacology across the five melanocortin receptors, including approved melanocortin-receptor agonists. Source · PMID 36291616
Literature notes: Most primary literature on this compound reports clinical endpoints and is outside the scope of this reference list.
Related Research Compounds
Browse more compounds in Melanocortin Peptides, or view the full research peptide catalogue.
Background on the compound: PT-141, melanocortin selectivity and the lactam bridge — receptor subtype profile, how it differs from melanotan-II, and what to check on the certificate.
Reviews
There are no reviews yet.